Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration
Open Access
- 7 June 2011
- journal article
- research article
- Published by Wiley in Journal of Drug Delivery
- Vol. 2011, 1-7
Abstract
Intraperitoneal (i.p.) administration of small interfering RNA (siRNA) has, to date, shown promise in treating tumours located within the peritoneal cavity. The ability of these siRNA molecules to reach extraperitoneal tumours following i.p. administration is, however, yet to be investigated. Here, we examined the impact of PEGylation on the biodistribution of i.p. administered nucleic acids-containing lipoplexes. We showed that in contrast to non-PEGylated liposomes, PEGylated liposomes can deliver siRNA efficiently to extraperitoneal tumours following i.p. administration, resulting in a 45% reduction in tumour size when the oncogene-targeted siRNA was used. This difference was likely contributed by the decreased uptake of PEGylated lipoplexes in the first-pass organs, and, in particular, we observed a 10-fold decrease in the macrophage uptake of these particles compared to non-PEGylated counterparts. Overall, our results indicated the potential of using PEGylated liposomes to deliver siRNA for the treatment of i.p. localized cancer with coexisting extraperitoneal metastasis.Keywords
Funding Information
- National Health and Medical Research Council (455890)
- Australian Cancer Research Foundation (455890)
- Cancer Council Queensland (455890)
This publication has 33 references indexed in Scilit:
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010
- Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse modelsGene Therapy, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Lipidic Systems for In Vivo siRNA DeliveryThe AAPS Journal, 2009
- Treatment of disseminated ovarian cancer using nonviral interleukin‐12 gene therapy delivered intraperitoneallyThe Journal of Gene Medicine, 2009
- Cationic PMMA Nanoparticles Bind and Deliver Antisense Oligoribonucleotides Allowing Restoration of Dystrophin Expression in the mdx MouseMolecular Therapy, 2009
- Sheddable Coatings for Long-Circulating NanoparticlesPharmaceutical Research, 2007
- Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneumJournal of Biomedical Materials Research Part A, 2006
- Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's DiseaseJournal of Neuroscience, 2005
- Transductional Efficacy and Safety of an Intraperitoneally Delivered Adenovirus Encoding an Anti-erbB-2 Intracellular Single-Chain Antibody for Ovarian Cancer Gene TherapyGynecologic Oncology, 1997